Erratum: Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor (Annals of Saudi Medicine (2016) 36: 3 (190-196) DOI: 10.5144/0256-4947.2016.190);Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs or anti-tumor necrosis factor

Annals of Saudi Medicine

Volumn 36, Issue 3, 2016, Pages 190-196

  Albattal, Basel M ^a  

^a Anemia and Transplantation   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; FOLINIC ACID; LACTATE DEHYDROGENASE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UREA; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DAS28; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; JOINT SWELLING; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MIDDLE AGED; PATHOPHYSIOLOGY; SAUDI ARABIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SAUDI ARABIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84981284248     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.5144/0256-4947.2017.338     Document Type: Erratum

References (8)

1. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. Kelley's Textbook of rheumatology. 7th ed. Philadelphia: W.B. Saunders, 2005:996-1042.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46:328-46.
3. Isenberg DA, Maddison PJ, Woo P, Glass D and Breedveld SD. Oxford Textbook of Rheumatology. Third edition. 2005.
4. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371:987-97.
5. Hoffmann- La Roche. Investigator drug brochure V.12; Sep 2010.
6. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial (RADIATE study). Ann Rheum Dis. 2008;67(11):1516-23.
7. Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibitsstructural joint damage in rheumatoid arthritis patientswith inadequate responsesto Methotrexate - results-from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention ofstructural joint damage at one year. Arthritis Rheum. 2011;63(3):609-621.
8. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a cochrane systematic review. J Rheumatol. 2011;38(1):10-20.